We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $67.89, marking a +0.64% move from the previous day. This change lagged the S&P 500's 1.17% gain on the day. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 0.18%.
Heading into today, shares of the company had gained 15.1% over the past month, outpacing the Medical sector's gain of 4.32% and the S&P 500's gain of 0.88% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.91 per share. This would mark a year-over-year decline of 26.49%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.67 million, up 949.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.96% higher within the past month. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $67.89, marking a +0.64% move from the previous day. This change lagged the S&P 500's 1.17% gain on the day. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 0.18%.
Heading into today, shares of the company had gained 15.1% over the past month, outpacing the Medical sector's gain of 4.32% and the S&P 500's gain of 0.88% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.91 per share. This would mark a year-over-year decline of 26.49%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.67 million, up 949.63% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.96% higher within the past month. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.